A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant ...

Kym Whitely is not opposed to bringing her Young & Hungry cast together again. Though the show, which ran from 2014 to 2018, ...

Roughly 16 million American adults are taking GLP-1 medications. They are a major breakthrough for people to shed pounds and ...

By Dennis Thompson HealthDay ReporterMONDAY, July 14, 2025 (HealthDay News) — Good news for women of a certain age: Hormone ...

Combing a weight-loss drug and hormone therapy may be the key to shedding pounds.

Some weight loss drugs may cause hair loss. While it’s typically a temporary side effect, it can affect your confidence.

SAN FRANCISCO -- Menopause hormone therapy (MHT) was tied to a weight-loss boost in postmenopausal women taking a weight loss ...

The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...

Concurrent use of menopausal hormone therapy may augment the weight loss benefits of tirzepatide for postmenopausal women ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...